EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Rhea-AI Summary
EyePoint Pharmaceuticals (NASDAQ:EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Dr. Jay S. Duker, President and CEO, will engage in a fireside chat on August 13, 2025, at 10:00 a.m. ET.
Investors can access the live webcast through the company's website, with a replay available for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EYPT declined 2.85%, reflecting a moderate negative market reaction. Argus tracked a trough of -8.7% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $22M from the company's valuation, bringing the market cap to $749M at that time.
Data tracked by StockTitan Argus on the day of publication.
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Thursday, August 13, 2025 at 10:00 a.m. ET.
A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data to date, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data anticipated in 2026. DURAVYU also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD is the leading cause of vision loss among people 50 years of age and older in the United States.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
When is EyePoint Pharmaceuticals (EYPT) presenting at the H.C. Wainwright Ophthalmology Conference?
How can investors access EyePoint's (EYPT) presentation at the H.C. Wainwright conference?
Who will be presenting for EyePoint Pharmaceuticals at the H.C. Wainwright conference?
What type of company is EyePoint Pharmaceuticals (EYPT)?
